Literature DB >> 19434927

Introduction and proliferation of multidrug-resistant Streptococcus pneumoniae serotype 19A clones that cause acute otitis media in an unvaccinated population.

Ron Dagan1, Noga Givon-Lavi, Eugene Leibovitz, David Greenberg, Nurith Porat.   

Abstract

BACKGROUND: Introduction of the 7-valent pneumococcal conjugate vaccine (PCV7) in the United States in 2000 was temporally associated with an increase in the incidence of disease caused by Streptococcus pneumoniae serotype 19A (Sp19A) and with increasing drug resistance within this serotype. A causative role of PCV7 was speculated. We prospectively studied the dynamics of acute otitis media (AOM) caused by Sp19A in southern Israel before the introduction of PCV7.
METHODS: AOM in children < 5 years old undergoing tympanocentesis during 1999-2006 was studied. Antibiotic prescriptions for approximately 20% of children < 5 years old were recorded. Sp19A isolates were studied for antibiotic-resistance and pulsed-field gel electrophoresis patterns; multilocus sequence typing of representative isolates was compared with that of international clones.
RESULTS: Sp19A caused 438 (9.8%) of 4449 pneumococcal AOM episodes, increasing by 63.1% from 1999-2001 (mean +/- SD, 8.4% +/- 0.8%) to 2004-2006 (mean +/- SD, 13.7% +/- 0.9%) among Bedouin children, who were characterized by overcrowding and high antibiotic use. Penicillin, erythromycin, and multidrug resistance increased from < 10% to 78.6%, 50.0%, and 50.0%, respectively (P < .001), and was associated with the introduction and proliferation of 2 multidrug-resistant clones that were not previously associated with multidrug resistance. This was temporally associated with the introduction of and rapid increase in azithromycin use and the frequent use of oral cephalosporins.
CONCLUSIONS: The introduction and proliferation of multidrug-resistant Sp19A occurred before the introduction of PCV7. The increasing proportion of antibiotic-resistant Sp19A suggests that antibiotic use plays an important role in the community.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19434927     DOI: 10.1086/597044

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  49 in total

1.  Developing the right pneumococcal vaccine for the time and place.

Authors:  Sanjay Mehta
Journal:  Am J Trop Med Hyg       Date:  2010-09       Impact factor: 2.345

2.  Pneumococcal vaccination: time to move on?

Authors:  Marijke Johanna Proesmans
Journal:  Eur J Pediatr       Date:  2010-05-15       Impact factor: 3.183

3.  Differential circulation of Streptococcus pneumoniae serotype 6C clones in two Israeli pediatric populations.

Authors:  Nurith Porat; In Ho Park; Moon H Nahm; Ron Dagan
Journal:  J Clin Microbiol       Date:  2010-10-13       Impact factor: 5.948

4.  In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.

Authors:  Brian J Morrow; Wenping He; Karen M Amsler; Barbara D Foleno; Mark J Macielag; A Simon Lynch; Karen Bush
Journal:  Antimicrob Agents Chemother       Date:  2010-02-22       Impact factor: 5.191

Review 5.  Serotype replacement in disease after pneumococcal vaccination.

Authors:  Daniel M Weinberger; Richard Malley; Marc Lipsitch
Journal:  Lancet       Date:  2011-04-12       Impact factor: 79.321

6.  Clonal evolution leading to maintenance of antibiotic resistance rates among colonizing Pneumococci in the PCV7 era in Portugal.

Authors:  Alexandra S Simões; Liliana Pereira; Sónia Nunes; António Brito-Avô; Hermínia de Lencastre; Raquel Sá-Leão
Journal:  J Clin Microbiol       Date:  2011-06-01       Impact factor: 5.948

7.  Clonality behind the increase of multidrug-resistance among non-invasive pneumococci in Southern Finland.

Authors:  L Siira; J Jalava; P Tissari; M Vaara; T Kaijalainen; A Virolainen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-08-26       Impact factor: 3.267

Review 8.  Panel 5: Microbiology and immunology panel.

Authors:  Timothy F Murphy; Tasnee Chonmaitree; Stephen Barenkamp; Jennelle Kyd; Johanna Nokso-Koivisto; Janak A Patel; Terho Heikkinen; Noboru Yamanaka; Pearay Ogra; W Edward Swords; Tania Sih; Melinda M Pettigrew
Journal:  Otolaryngol Head Neck Surg       Date:  2013-04       Impact factor: 3.497

Review 9.  Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A?

Authors:  William P Hausdorff; Bernard Hoet; Lode Schuerman
Journal:  BMC Pediatr       Date:  2010-02-02       Impact factor: 2.125

10.  Baseline epidemiology and genetic structure of Streptococcus pneumoniae serotype 6D in southern Israel prior to introduction of pneumococcal conjugate vaccines.

Authors:  Nurith Porat; Rachel Benisty; Ronit Trefler; Doreen Ozalvo; Noga Givon-Lavi; Ron Dagan
Journal:  J Clin Microbiol       Date:  2013-02-27       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.